Posted On: 01/15/2016 9:07:49 AM
Post# of 94162
RXMD: There was some exposure from SeekingAlpha article the other day. Highlights are below as well as a link to the original article.
Back in August, I highlighted a smaller pharmacy company in South Florida, Progressive Care, Inc. (OTCPK:RXMD) through its subsidiary PharmCo LLC. At the time the stock was trading well under a penny and had just been issued an analyst target of $0.03. Strong revenue growth, filled prescriptions, and the extinguishment of its remaining debt (from a total of $1.8m plus fees) have lead the stock to rally over the last 5 months to highs of $0.033 thus beating analysts short term targets. Recent headlines show, too, that the company has advanced to OTC current status as of Friday January 8th.
Several key standouts to Progressive include month over month, quarter over quarter, and quite possibly year over year growth in revenue, filled prescriptions, and further expansion of its compounding division as well as the new venture into the 340B market. As of the close of 2014, the company had done $11m in total revenue with a heavy debt position on its books. As of the last filed quarterly report, Progressive showed 9 months' revenue of $9.7million.
Assuming the company continues to average roughly $1m a month, Progressives 2015 operating results related to revenues alone should outpace the 2014 numbers by nearly $2million (Assuming $1.07million per month times 3 months remaining to report equates to an additional $3.21million). Pharmacy stocks both large and small cap will remain on my safe haven list for the first half of 2016 and most likely for the foreseeable future as baby boomer populations continue to rise and the need for specialized medicines, IE compound medications, continue to grow.
http://seekingalpha.com/instablog/10425141-sm...-the-storm
Back in August, I highlighted a smaller pharmacy company in South Florida, Progressive Care, Inc. (OTCPK:RXMD) through its subsidiary PharmCo LLC. At the time the stock was trading well under a penny and had just been issued an analyst target of $0.03. Strong revenue growth, filled prescriptions, and the extinguishment of its remaining debt (from a total of $1.8m plus fees) have lead the stock to rally over the last 5 months to highs of $0.033 thus beating analysts short term targets. Recent headlines show, too, that the company has advanced to OTC current status as of Friday January 8th.
Several key standouts to Progressive include month over month, quarter over quarter, and quite possibly year over year growth in revenue, filled prescriptions, and further expansion of its compounding division as well as the new venture into the 340B market. As of the close of 2014, the company had done $11m in total revenue with a heavy debt position on its books. As of the last filed quarterly report, Progressive showed 9 months' revenue of $9.7million.
Assuming the company continues to average roughly $1m a month, Progressives 2015 operating results related to revenues alone should outpace the 2014 numbers by nearly $2million (Assuming $1.07million per month times 3 months remaining to report equates to an additional $3.21million). Pharmacy stocks both large and small cap will remain on my safe haven list for the first half of 2016 and most likely for the foreseeable future as baby boomer populations continue to rise and the need for specialized medicines, IE compound medications, continue to grow.
http://seekingalpha.com/instablog/10425141-sm...-the-storm
(0)
(0)Scroll down for more posts ▼
